Advanced

Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.

Hansson, Oskar LU ; Buchhave, Peder LU ; Zetterberg, Henrik; Blennow, Kaj; Minthon, Lennart LU and Warkentin, Siegbert LU (2009) In Neurobiology of Aging 30(2). p.165-173
Abstract
This study aimed to identify preclinical Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) using measurements of both regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) biomarkers. Baseline rCBF assessments (133Xe method) were performed in 70 patients with MCI who were cognitively stable for 4–6 years, 69 patients with MCI who subsequently developed AD, and 33 healthy individuals. CSF was collected at baseline and analyzed for β-amyloid1–42, total tau and phophorylated tau. In contrast to patients with stable MCI, those who subsequently developed AD had decreased rCBF in the temporo-parietal cortex already at baseline. The relative risk of future progression to AD was particularly increased in MCI... (More)
This study aimed to identify preclinical Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) using measurements of both regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) biomarkers. Baseline rCBF assessments (133Xe method) were performed in 70 patients with MCI who were cognitively stable for 4–6 years, 69 patients with MCI who subsequently developed AD, and 33 healthy individuals. CSF was collected at baseline and analyzed for β-amyloid1–42, total tau and phophorylated tau. In contrast to patients with stable MCI, those who subsequently developed AD had decreased rCBF in the temporo-parietal cortex already at baseline. The relative risk of future progression to AD was particularly increased in MCI patients with decreased rCBF in parietal cortex (hazard ratio 3.1, P < 0.0001). Subjects with pathological levels of both CSF tau and β-amyloid1–42 were also at high risk of developing AD (hazard ratio 13.4, P < 0.0001). The MCI patients with a combination of decreased parietal rCBF and pathological CSF biomarkers at baseline had a substantially increased risk of future development of AD, with a hazard ratio of 24.3 (P < 0.0001), when compared to those with normal CSF biomarkers. Moreover, decreased parietal rCBF (but not CSF biomarkers) was associated with a more rapid progression to AD. In conclusion, the combination of rCBF and CSF biomarkers improves the risk assessment of progression to AD in patients with MCI. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Regional cerebral blood flow, Biomarkers, Alzheimer's disease, Tau, Cerebrospinal fluid, Beta-amyloid, Mild cognitive impairment
in
Neurobiology of Aging
volume
30
issue
2
pages
165 - 173
publisher
Elsevier
external identifiers
  • wos:000262249100001
  • scopus:57749091995
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2007.06.009
language
English
LU publication?
yes
id
a6307b58-5c1a-45d6-88c6-1998bd50672b (old id 540561)
date added to LUP
2008-08-20 15:45:25
date last changed
2017-11-26 03:18:38
@article{a6307b58-5c1a-45d6-88c6-1998bd50672b,
  abstract     = {This study aimed to identify preclinical Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) using measurements of both regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) biomarkers. Baseline rCBF assessments (133Xe method) were performed in 70 patients with MCI who were cognitively stable for 4–6 years, 69 patients with MCI who subsequently developed AD, and 33 healthy individuals. CSF was collected at baseline and analyzed for β-amyloid1–42, total tau and phophorylated tau. In contrast to patients with stable MCI, those who subsequently developed AD had decreased rCBF in the temporo-parietal cortex already at baseline. The relative risk of future progression to AD was particularly increased in MCI patients with decreased rCBF in parietal cortex (hazard ratio 3.1, P &lt; 0.0001). Subjects with pathological levels of both CSF tau and β-amyloid1–42 were also at high risk of developing AD (hazard ratio 13.4, P &lt; 0.0001). The MCI patients with a combination of decreased parietal rCBF and pathological CSF biomarkers at baseline had a substantially increased risk of future development of AD, with a hazard ratio of 24.3 (P &lt; 0.0001), when compared to those with normal CSF biomarkers. Moreover, decreased parietal rCBF (but not CSF biomarkers) was associated with a more rapid progression to AD. In conclusion, the combination of rCBF and CSF biomarkers improves the risk assessment of progression to AD in patients with MCI.},
  author       = {Hansson, Oskar and Buchhave, Peder and Zetterberg, Henrik and Blennow, Kaj and Minthon, Lennart and Warkentin, Siegbert},
  issn         = {1558-1497},
  keyword      = {Regional cerebral blood flow,Biomarkers,Alzheimer's disease,Tau,Cerebrospinal fluid,Beta-amyloid,Mild cognitive impairment},
  language     = {eng},
  number       = {2},
  pages        = {165--173},
  publisher    = {Elsevier},
  series       = {Neurobiology of Aging},
  title        = {Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.},
  url          = {http://dx.doi.org/10.1016/j.neurobiolaging.2007.06.009},
  volume       = {30},
  year         = {2009},
}